Karyopharm Therapeutics Inc. 宣布,其计划于8月提交的补充新药申请(sNDA)正在按既定时间表稳步推进。该申请旨在寻求批准Selinexor与Ruxolitinib的联合疗法,用于治疗骨髓纤维化患者。这一进展标志着公司在关键临床试验成果转化道路上迈出了坚实的一步,为期待新疗法的病患群体带来了潜在希望。
Karyopharm Therapeutics Inc. 宣布,其计划于8月提交的补充新药申请(sNDA)正在按既定时间表稳步推进。该申请旨在寻求批准Selinexor与Ruxolitinib的联合疗法,用于治疗骨髓纤维化患者。这一进展标志着公司在关键临床试验成果转化道路上迈出了坚实的一步,为期待新疗法的病患群体带来了潜在希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.